Trends of Norfloxacin and Erythromycin Resistance ofCampylobacter jejuni/Campylobacter coliIsolates Recovered From International Travelers, 1994 to 2006
Open Access
- 1 November 2008
- journal article
- Published by Oxford University Press (OUP) in Journal of Travel Medicine
- Vol. 15 (6), 419-425
- https://doi.org/10.1111/j.1708-8305.2008.00236.x
Abstract
Campylobacter sp. is a major cause of bacterial enterocolitis and travelers’ diarrhea. Empiric treatment regimens include fluoroquinolones and macrolides. Over the period 1994 to 2006, 724 Campylobacter jejuni/Campylobacter coli isolates recovered from international travelers at the outpatient clinic of the Institute of Tropical Medicine, Antwerp, Belgium, were reviewed for their susceptibility to norfloxacin and erythromycin. Norfloxacin resistance increased significantly over time in isolates from travelers returning from Asia, Africa, and Latin America. For the years 2001 to 2006, norfloxacin resistance rates were 67 (70.5%) of 95 for Asia, 20 (60.6%) of 33 for Latin America, and 36 (30.6%) of 114 for Africa. The sharpest increase was noted for India, with no resistance in 1994, but 41 (78.8%) of 52 resistant isolates found during 2001 to 2006. Erythromycin resistance was demonstrated in 20 (2.7%) isolates, with a mean annual resistance of 3.1% ± 2.8%; resistance increased over time, with up to 3(7.5%) of 40 and 3 (8.6%) of 35 resistant isolates in 2004 and 2006, respectively (p < 0.05); there was no apparent geographic association. Combined resistance to norfloxacin and erythromycin was observed in five isolates. The high resistance rates to fluoroquinolones warrant reconsideration of their use as drugs of choice in patients with severe gastroenteritis when Campylobacter is the presumed cause. Continued monitoring of the incidence and the spread of resistant Campylobacter isolates is warranted.Keywords
This publication has 38 references indexed in Scilit:
- The Health Burden of Campylobacter Infection and the Impact of Antimicrobial Resistance: Playing ChickenClinical Infectious Diseases, 2007
- Regional risks and seasonality in travel-associated campylobacteriosisBMC Infectious Diseases, 2004
- Fluoroquinolone Resistance inCampylobacter jejuniIsolates in Travelers Returning to Finland: Association of Ciprofloxacin Resistance to Travel DestinationEmerging Infectious Diseases, 2003
- Human Campylobacteriosis in Developing CountriesEmerging Infectious Diseases, 2002
- Practice Guidelines for the Management of Infectious DiarrheaClinical Infectious Diseases, 2001
- Quinolone and Macrolide Resistance in Campylobacter jejuni and C. coli: Resistance Mechanisms and Trends in Human IsolatesEmerging Infectious Diseases, 2001
- Quinolone-ResistantCampylobacter jejuniInfections in Minnesota, 1992–1998New England Journal of Medicine, 1999
- Trends in Antibiotic Resistance Among Diarrheal Pathogens Isolated in Thailand Over 15 YearsClinical Infectious Diseases, 1998
- Norfloxacin resistance in Campylobacter jejuni and Campylobacter coli isolates from Swedish patientsJournal of Antimicrobial Chemotherapy, 1997
- Ciprofloxacin- and Azithromycin-Resistant Campylobacter Causing Traveler's Diarrhea in U.S. Troops Deployed to Thailand in 1994Clinical Infectious Diseases, 1996